Articles
Page 16 of 19
-
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P313
-
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P311 -
Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the USA
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P309 -
Cost-effectiveness of switching to second-line therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P307 -
Perceptions of obesity amongst a mixed HIV cohort in London, UK – Slim is no longer Slim
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P305 -
Abstract withdrawn
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P281 -
Substitution of tenofovir for nucleoside analogues in virologically controlled HIV-infected patients co-infected with hepatitis C virus: TEN-SWITCH
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P277 -
Presence of hepatitis B virus in cerebrospinal fluid of HIV-1 co-infected adolescents
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P275 -
Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimen
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P273 -
Frequency of hepatic steatosis in HIV and hepatitis C co-infected patients treated by antiretroviral therapy during 1995 to 2008
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P269 -
Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P244 -
Quantitation of raltegravir in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of LC-MS/MS
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P242 -
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P240 -
Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P238 -
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P236 -
Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P234 -
Reproducibility of a high-throughput HIV-1 genotypic resistance assay over time (2001–2007)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P205 -
Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P203 -
Determination of HIV-1 co-receptor usage in German patients – comparison of genotypic methods with the TROFILE® phenotypic assay
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P201 -
Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected with Clade C virus
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P198 -
Loss to follow-up in HIV immigrant patients. Is it a relevant problem? Results of the Spanish COMESEM cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P173 -
Dispositional optimism, perceived health competence and adherence in highly antiretroviral-experienced patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P171 -
Factors correlated to non-adherence to antiretroviral therapy among immigrants from poor resource countries, attending a reference center in Rome
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P169 -
Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P167 -
Risk factors and clinical and therapeutic issues of pancreatic abnormalities during HIV infection
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P165 -
Neurotoxic effect of antiretroviral agents on CNS
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P163 -
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P136 -
Introduction of a system to screen for chronic kidney disease and monitor for nephrotoxicity of antiretrovirals at an outpatient HIV clinic
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P132 -
Subclinical kidney disease in HIV-infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P130 -
Kidney tubular abnormalities in HIV patients treated with tenofovir with normal glomerular function – results of a prospective study on 284 patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P128 -
Hypertension is the most common component of the metabolic syndrome in a cohort of NRTI-based HAART treated patients – a preliminary report
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P126 -
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on PR interval: results from a thorough QT study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P101 -
KAPITAL2: a study of treatment satisfaction reported by patients on lopinavir/r anchored regimens and physicians who provide HIV care
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P80 -
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P76 -
Patient characteristics and treatment outcomes associated with protease inhibitor (PI) use in the Asia-Pacific region
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P72 -
A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimen
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P68 -
L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P43 -
Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment options
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P41 -
Darunavir exhibits a potent activity as boosted PI in subjects on a salvage antiretroviral regimen
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P39 -
Switching from enfuvirtide to etravirine – efficacy results from the etravirine expanded access programme
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P37 -
O331 Patterns of viral suppression on cART as predictors of uncontrolled viremia after starting a new antiretroviral after 1 January 2003
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O35 -
Antiretroviral treatment efficacy after mutations reversion during T20 monotherapy, an alternative strategy in multi-failed HIV-1 infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P35 -
O323 High HIV viral load inhibits osteoblast function and signalling
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O33 -
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P33 -
O321 Management of renal disease in HIV infection for the HIV physician
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O31 -
INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P29 -
O311 Pathogenesis of non-AIDS morbidities in HIV disease and implications for management
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O27 -
O232 What's new in hepatitis C?
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O25 -
A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P6 -
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naïve patients through 7 years
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P4